Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma

International Journal of Cancer

Volumn 129, Issue 9, 2011, Pages 2297-2303

  Eisenhardt, Anja E ^a   Olbrich, Heike ^b,c   Röring, Michael ^a   Janzarik, Wibke ^b   Anh, Ton Nu Van ^b   Cin, Huriye ^d   Remke, Marc ^d,e   Witt, Hendrik ^d,e   Korshunov, Andrey ^d   Pfister, Stefan M ^d,e   Omran, Heymut ^a,b,c   Brummer, Tilman ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

B Raf; insertion mutagenesis; MAPK pathway; neurofibromatosis type 1; pilocytic astrocytoma

Indexed keywords

AMINO ACID DERIVATIVE; B RAF KINASE; GLUTAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; NEUROFIBROMIN; PROTEIN KINASE; RAS PROTEIN; THREONINE; VALINE;

ADOLESCENT; ADULT; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE DUPLICATION; GENE INSERTION; GENETIC CONSERVATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

ADOLESCENT; ADULT; ALLELES; ANIMALS; ASTROCYTOMA; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHILD, PRESCHOOL; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MUTAGENESIS, INSERTIONAL; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; YOUNG ADULT;

EID: 80052273582     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25893     Document Type: Article

References (25)

1. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS,. BRAF(E600) in benign and malignant human tumours. Oncogene 2008; 27: 877-95. (Pubitemid 351225383)
2. Tatevossian RG, Lawson AR, Forshew T, Hindley GF, Ellison DW, Sheer D,. MAPK pathway activation and the origins of pediatric low-grade astrocytomas. J Cell Physiol 2010; 222: 509-14.
3. Galabova-Kovacs G, Catalanotti F, Matzen D, Reyes GX, Zezula J, Herbst R, Silva A, Walter I, Baccarini M,. Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development. J Cell Biol 2008; 180: 947-55. (Pubitemid 351398421)
4. Zhang BH, Guan KL,. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 2000; 19: 5429-39.
5. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R,. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-67. (Pubitemid 38410730)
6. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-5.
7. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N,. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464: 427-30.
8. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R,. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-21.
9. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54. (Pubitemid 34716871)
10. Pfister S, Witt O,. Pediatric gliomas. Recent Results Cancer Res 2009; 171: 67-81.
11. Brummer T, Martin P, Herzog S, Misawa Y, Daly RJ, Reth M,. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein. Oncogene 2006; 25: 6262-76. (Pubitemid 44564743)
12. Moretti S, Macchiarulo A, De Falco V, Avenia N, Barbi F, Carta C, Cavaliere A, Melillo RM, Passeri L, Santeusanio F, Tartaglia M, Santoro M, et al. Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 2006; 25: 4235-40. (Pubitemid 44079457)
13. Edlundh-Rose E, Egyhazi S, Omholt K, Mansson-Brahme E, Platz A, Hansson J, Lundeberg J,. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006; 16: 471-8. (Pubitemid 44934704)
14. Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, Toedt G, Wittmann A, Kratz C, Olbrich H, Ahmadi R, Thieme B, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008; 118: 1739-49. (Pubitemid 351632377)
15. Jacob K, Albrecht S, Sollier C, Faury D, Sader E, Montpetit A, Serre D, Hauser P, Garami M, Bognar L, Hanzely Z, Montes JL, et al. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer 2009; 101: 722-33.
16. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP,. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008; 68: 8673-7.
17. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P,. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109. (Pubitemid 47103521)
18. Yu J, Deshmukh H, Gutmann RJ, Emnett RJ, Rodriguez FJ, Watson MA, Nagarajan R, Gutmann DH,. Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology 2009; 73: 1526-31.
19. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP,. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009; 28: 2119-23.
20. Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, Jones TA, Aarum J, Dalton J, Bailey S, Chaplin T, Carter RL, et al. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009; 218: 172-81.
21. Janzarik WG, Kratz CP, Loges NT, Olbrich H, Klein C, Schafer T, Scheurlen W, Roggendorf W, Weiller C, Niemeyer C, Korinthenberg R, Pfister S, et al. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics 2007; 38: 61-3. (Pubitemid 47434497)
22. Sharma MK, Zehnbauer BA, Watson MA, Gutmann DH,. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 2005; 65: 1335-6. (Pubitemid 41508250)
23. Robinson JP, VanBrocklin MW, Guilbeault AR, Signorelli DL, Brandner S, Holmen SL,. Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene 2010; 29: 335-44.
24. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 2010; 70: 512-19.
25. Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, Storm PB, Biegel JA,. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 2010; 12: 621-30.